HTFL

Heartflow, Inc. (HTFL) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Heartflow, Inc. is a commercial-stage medical technology company providing AI-driven software for non-invasive diagnosis and management of coronary artery disease (CAD). The company operates as a single reporting segment. As of the reporting date, the company is an emerging growth company and a non-accelerated filer. The company completed its Initial Public Offering (IPO) in August 2025.

Key Financial Metrics

Liquidity: As of March 31, 2026, the company held $19.7 million in cash and cash equivalents, $138.6 million in short-term investments, and $96.6 million in long-term investments. Management believes existing resources are sufficient to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 41% year-over-year to $52.6 million, driven primarily by a 67% increase in revenue case volume (67,443 cases in Q1 2026 vs. 40,336 in Q1 2025). This was partially offset by a reduction in average sales price due to a higher mix of clinic/office-based accounts and increased volume rebates.
• Operating Expenses: Total operating expenses increased 60% to $71.7 million.
  • R&D: Increased 55% to $21.6 million due to higher headcount and consulting fees.
  • SG&A: Increased 35% to $42.6 million, driven by personnel costs and public company compliance expenses.
  • Asset Impairment: A non-cash impairment charge of $7.5 million was recorded in Q1 2026 related to the right-of-use asset and leasehold improvements for the Mountain View, CA facility following a sublease agreement. No such charge existed in Q1 2025.
• Interest & Other Income: Interest income increased to $2.5 million (from $0.5 million) due to higher investment yields. Interest expense and derivative liability charges present in Q1 2025 were eliminated in Q1 2026 following the repayment of the 2024 Term Loan and conversion of 2025 Convertible Notes upon the IPO.

Outlook, Risks, and Unusual Items

• Guidance: The filing does not provide specific numerical financial guidance for the full year 2026. Management expects to continue incurring losses as it scales operations and invests in R&D and commercial expansion.
• Product Launches: Heartflow PCI Navigator was launched in April 2026. Plaque Tracker is anticipated to launch in 2027.
• Legal Proceedings:
  • DOJ Investigation: In October 2025, the company received Civil Investigative Demands (CID) from the U.S. Department of Justice regarding the Anti-Kickback Statute and Civil False Claims Act. The company is cooperating, but the outcome and financial impact are currently indeterminable.
  • Patent Litigation: On April 13, 2026, Heartflow filed a patent infringement lawsuit against Cleerly, Inc., alleging infringement of six patents related to Heartflow's technology.
• Risks: Key risks include dependence on the Heartflow FFR CT Analysis product (98% of cumulative revenue), reimbursement policies from third-party payors, competition, and the ability to achieve profitability.

Investor Verification Checklist

• Impairment Charge: Verify the details of the $7.5 million asset impairment charge related to the Mountain View facility sublease and its impact on future lease obligations.
• DOJ Investigation: Monitor updates regarding the Department of Justice investigation into financial arrangements and sales activities; assess potential for fines or operational restrictions.
• Revenue Mix: Analyze the shift toward clinic/office-based accounts and its long-term impact on average sales price and gross margins.
• Cash Burn: Review the $30.1 million operating cash outflow and the trajectory of the accumulated deficit ($1.1 billion) relative to the $254.9 million cash position.
• Patent Litigation: Track the progress of the lawsuit against Cleerly, Inc. and potential impacts on market share or legal costs.